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ATHEROCENIC ACTIVITY OF EXCESS EMmANE CHOLESTEROL 
IN ARTERIAL SMooTH USCLE AND ENDOTHELIAL CELLS 
Thomas N. Tulenko. Department of Physiology/Biochemistry, 
Medical College 01 Pennsylvania., Philadelphia, PA 19129. 
The ability of free (unesterified) cholesterol (FC) to alter 
cellular growth rates was examined in rabbit aoriic smooth muscle 
(SMC) and human endolhelial cells (EC) in culture. In the 2nd 
passage, the cells were growth arrested in 1%FBS for 7 days, 
followed by incubation over 4 days with FC/phospholipid (FC/PL) 
liposomes In a 2:l molar ratio. This incubation resulted in a 4-5 
fold increase in cell number and was accompanied by a 70% 
increase in cell FC content and similar increase in membrane FC 
content. In SMC, this incubation also increased )5Ca+* influx 
through a dihydropyridine (DHP)-sensitive pathway, and Ihe FC 
proliferative response was blocked by diltiazem (0.1 nM) and 
amlodipine (0.1 PM). F&free liposomes had no effect on 
proliferalion. The proliferahve response lo FC was similar 10 lhal 
obtained with PDGF (6 nfwl) and greater (2x) than that obtained 
with FGF (30 r&l). The mitogenic activity of PDGF and FGF was 
antagonized by amlodipine (0.1 PM), and that of PDGF, FGF and FC 
was also antagonized by heparin (10 PM) and staurosporin (10 
nM). FC-enrichment had a similar amlodipine-sensitive effect on 
human EC proliferative activity. In separate experiments, aortic 
SMC isolated from dietary atherosclerotic rabbits aiso 
demonstrated an Increase in membrane FC content as well as 
amlodipine-sensitive increased Wa+* influx and amlodipine- 
sensitive increased proliferative activiiy. Taken together, these 
data indicate that FC has potent mitogenic activity on arterial SMC 
and EC, and may explain Ihe initial ‘injury’ to these cells in situ 
and the early proliferative response in atherogenesis. In addition, 
the sensitivity to the calcium channel blockers, and especially 
amlodipine, may explain the ability of lhese compounds to retard 
lesion development in experimental and human atherosclerosis. 
(Support: NIH HL 30496; AHA-Delaware; AHA-SE Chapter, PA) 
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Smooth muscle proliferation is the most prominent feature of 
the blo$ vessel Fspon.se to m+hanical Injury. Accordingly, 
qodulation 0.f prohferahon has important therapeutic implica- 
trons for angloplasty restenosis. We have recently identified a 
subclass of thiol protease inhibitors (TPI) that reversibly inhibit 
bovine aortic smooth muscle cell (BASK) 
vitro. In order to further define the nature o P 
roliferation in 
this inhibition, 
two-color flow cytometry (FCM) and Northern analysis of 
mRNA were employed. FCM was performed using propidium 
iodide and fluorescein-labeled anti-bromodeox ridinc demon- 
strating total and synthesized DNA, respective y. Treatment of f 
BASMC with benzyloxycarbonyl-leu-norleucinal (C lpeptin) at 
1OOrM and acetyl-leu-leu-norleucinal (TPI-1) at SO&¶ was 
shown !o ca+e a ‘ulock of serum-inducibld cell c$cle progression 
at a point pnor to the Gl-S boundary, reducing the percentage 
of bromodeoxyuridine-positive c lls from 87 to 5 over a 24 hr 
labeling period. Addition of TPI-1 at various times followine 
serum addlhon to serum-deprived BASMC showed 80% of the- 
maximal block of DNA synthesis even when added 6 hrs after 
serum. Block of cell cycle progression was gradual1 
delay from serum to TPI-1 application was incr eastd 
lost as the 
from 6 to 
12 hrs. By Northern analysis of mRNA following serum addi- 
tion, PI-1 caused a $-fold decrease in the transient elevation of 
fos proto-oncogene a; well as a decrease in the levels of both 
muscle and non-muscle actin mRNA induced early after serum 
addition. Combined with FCM data, these results suggest more 
than one molecular site of inhibition of the progression from Gl 
to S phase. We postulate that these thiol protease inhibitors 
could be useful in the tnatment of angioplasty restenosis. 
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ACETYLATED LOW DENSITY LlPOP~OTElN 
TNF, IL-lbeta AND IL-8 EXPRESSION IN R i?i 
MONOCYTE DERIVED 
Peter Barath, Jin Gao, mes Forrester, Cedars-Sinai 
Center, Los Angeles, 6 
LDL is an activator of protein kinase 6 ( 
hypothesized LDL may activate tumor necrosis fa 
interleukins (IL-lbeta and/or 11-6) whose expression is PKC 
mediated. The goals of this study were: 1) to determine the 
effect of aLDL on cytokine expression in monocyte derived 
macroohanes: and 2) to determine dose dependencv and 
time c&s< of this eff& 
period in DMEM and lipoprotein deficient serum human 
inon?rytes from buffy coat’ were incubated in se:um free 
our increments. 
in the system which had no 
cted and the accumulation of 
mRNA was detected by Northern blot 
sured by ELISA. 
ndent accumulati 
cytokines with a maximal signal at 250 uglml at 6 hour: 
returning to the control level at 18 hours. At a concentration oi 
500 ug/?iI aLDL downregulated mRNA accumulation. IL-6 had 
the stronnest sinnal followed bv IL-1 and TNF. ELISA revealed 
a conce&ation-2-3 times abode the control protein levels for 
all three cytokines. Conclusions: 1) aLDL is a 
both mRNA and protein production of cyt 
monocyte derived‘macrophages; and 2) ttie induction shows 
dose dependency and a time course consistent with 
transcriptional activation. This induction may be a potential 
mechanism in atheroma evolution. 
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1 BROELAST AND TRANSFORMING GRO TH FACTORS IN ENDOTHELlAL 
OUHD HEALING IN VITRO 
Sadatashi Birg, Zu-Xi Yu, ard Casscells. NHLBI, 
Bethesda, ND 
Endothelial proliferation and migration are essential 
features of wound healing. The mechanisms responsible 
sses are still, however, incompletely 
e have examined the role of fibroblast 
growth factor (FGF) and transforming growth factor-B1 
(TGFB) on these processes. Confluent monolayers of 
bovine coronary artery (CA), coronary sinus (CS), and 
adrenal capillary (AC] endothelial cells in 2-10X calf 
serum exhibited different modes of migration: CA and CS 
as sheets, AC as individuals; and diffe 
fastest, AC slowest, and CS variable. 
all 3 exhibited increased inrmunoreactivity for basic 
fibroblast growth factor (bFGF) using specific polyclonal 
and monoclonal sera, beginning 2-6h after wounding. The 
increase was blocked by cycloheximide (which prevented 
TGF-B healing) but not by TGF-B, though TGFB slowed 
healing, evidently by a mechanism independent of bFGF. 
Despite increased bFGF synthesis, adding bFGF sped 
healing. Anti-bFGF receptor staining was noted in 
migrating but not quiescent cells. Monoclonal anti-bFGF 
slowed but did not prevent healing in 0.5 or 10% serum, 
suggesting intracrine bFGF function or use of other 
growth factors. These data suggest the possibility of 
using bFGF or anti-TGFB to enhance endothelialization of 
vascular wounds and prostheses, or to speed the initial 
step (migration) in angiogenesis of infarcted or ischemic 
tissue. 
